OMEROS CORP OMER

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Omeros Corporation ("Omeros," the "Company" or "we") is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.

Our complement-targeted product, product candidates, and therapeutic programs are primarily focused on diseases and disorders associated with the lectin and/or alternative pathways of complement. Our lectin pathway program includes inhibitors of mannan-binding lectin-associated serine protease 2 ("MASP-2") and our alternative pathway program includes inhibitors of mannan-binding lectin-associated serine protease 3 ("MASP-3").

Last close 16.57 2026-10-23
Market cap $1.20B 2026-06-30 share count
52-week range 6.24 - 21.24

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.05

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —————$73.8M$111.8M$29.9M$64.8M$41.6M
Cost of revenue —————$902.0K$865.0K$512.0K$1.1M$1.4M
Gross profit —————$72.9M$110.9M$29.4M$63.7M$40.2M
R&D $81.3M$119.5M$114.9M$112.7M$118.8M$107.6M$106.3M$89.9M$55.6M$50.7M
SG&A $41.5M$47.4M$49.7M$50.7M$54.8M$49.3M$39.7M$51.7M$52.0M$43.8M
Total operating expenses $122.8M$167.0M$164.5M$163.4M$173.6M$156.9M$146.0M$142.1M$108.7M$95.9M
Operating income -$122.8M-$167.0M-$164.5M-$163.4M-$173.6M-$156.9M-$146.0M-$112.2M-$43.9M-$54.3M
Interest expense $960.0K$24.7M$30.8M$22.7M$19.7M$26.8M$22.7M$16.3M$11.0M$7.8M
Pre-tax income -$2.8M-$180.3M-$174.9M-$182.0M-$191.5M-$196.4M-$167.1M-$139.7M-$53.5M-$66.7M
Income tax $2.0M$2.3M$0$0$0$23.3M$19.8M$12.9M$0$0
Net income -$3.4M-$156.8M-$117.8M$47.4M$194.2M-$138.1M-$84.5M-$126.8M-$53.5M-$66.7M
EPS, basic -0.05-2.70-1.880.763.12-2.41-1.71———
EPS, diluted -0.05-2.70-1.880.763.12-2.41-1.71-2.61-1.17-1.65
Shares, diluted (wtd. avg.) 63.5M58.2M62.7M62.7M62.3M57.2M49.5M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $9.7M$3.4M$7.1M$11.0M$100.8M$10.5M$3.1M$5.9M$3.4M$2.2M
Short-term investments $162.1M$86.7M$164.7M$183.9M$56.5M$124.5M$57.7M$54.6M——
Receivables $10.9M$7.7M$8.1M$213.2M$38.2M$3.8M$35.2M$22.8M$17.1M$12.0M
Inventory —————$1.4M$1.1M$88.0K$443.0K$1.1M
Total current assets $215.7M$134.1M$217.9M$443.2M$248.0M$151.3M$103.7M$89.9M$108.4M$60.3M
Property, plant and equipment $1.8M$2.7M$1.9M$1.5M——$3.8M$3.8M$2.1M$1.2M
Total assets $325.6M$277.1M$378.3M$591.0M$419.3M$181.0M$137.0M$95.9M$116.3M$67.3M
Accounts payable $4.8M$5.9M$7.7M$6.0M$13.4M$4.2M$5.3M$6.3M$6.7M$2.5M
Short-term debt ———————$889.0K$490.0K$198.0K
Total current liabilities $78.1M$79.5M$53.3M$136.4M$51.8M$36.7M$55.5M$37.4M$26.3M$16.1M
Long-term debt $87.9M$164.9M$213.2M$315.3M$313.5M$236.3M——$84.1M$79.5M
Retained earnings -$913.7M-$910.3M-$753.5M-$635.7M-$683.1M-$872.7M-$734.6M-$650.1M-$523.4M-$469.9M
Total equity -$121.2M-$182.6M-$25.0M$85.7M$23.8M-$120.8M-$109.0M-$100.2M-$2.8M-$37.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$116.1M-$148.8M$74.7M-$86.5M-$109.7M-$100.1M-$60.1M-$103.7M-$36.2M-$51.5M
Depreciation and amortisation $964.0K$950.0K$920.0K$952.0K$1.4M—————
Stock-based compensation $8.2M$10.5M$11.7M$14.1M$17.6M$14.9M$13.8M$11.7M$12.7M$13.6M
Capital expenditure $65.0K$165.0K$426.0K$113.0K$277.0K$283.0K$334.0K$567.0K$350.0K$126.0K
Investing cash flow $164.5M$82.2M$27.5M-$127.6M$193.7M-$67.0M-$3.4M$25.2M-$37.6M-$16.3M
Financing cash flow -$42.2M$62.9M-$106.1M$124.2M$6.3M$174.5M$60.7M$81.1M$75.0M$68.7M
Buybacks $0$11.9M$4.7M$0$0—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-010636.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M -100M 0 100M 200M Revenue, FY2016: 41.6M Gross profit, FY2016: 40.2M Net income, FY2016: -66.7M Revenue, FY2017: 64.8M Gross profit, FY2017: 63.7M Net income, FY2017: -53.5M Revenue, FY2018: 29.9M Gross profit, FY2018: 29.4M Net income, FY2018: -126.8M Revenue, FY2019: 111.8M Gross profit, FY2019: 110.9M Net income, FY2019: -84.5M Revenue, FY2020: 73.8M Gross profit, FY2020: 72.9M Net income, FY2020: -138.1M Net income, FY2021: 194.2M Net income, FY2022: 47.4M Net income, FY2023: -117.8M Net income, FY2024: -156.8M Net income, FY2025: -3.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $41.6M $64.8M $29.9M $111.8M $73.8M — — — — —
Gross profit $40.2M $63.7M $29.4M $110.9M $72.9M — — — — —
Net income -$66.7M -$53.5M -$126.8M -$84.5M -$138.1M $194.2M $47.4M -$117.8M -$156.8M -$3.4M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Other event Item 8.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%